Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients

Shinji Kawabata, Shin Ichi Miyatake, Naosuke Nonoguchi, Ry Hiramatsu, Kyoko Iida, Shiro Miyata, Kunio Yokoyama, Atsushi Doi, Yuzo Kuroda, Toshihiko Kuroiwa, Hiroyuki Michiue, Hiroaki Kumada, Mitsunori Kirihata, Yoshio Imahori, Akira Maruhashi, Yoshinori Sakurai, Minoru Suzuki, Shin Ichiro Masunaga, Koji Ono

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: Since 2002-2007, we applied boron neutron capture therapy (BNCT) to >50 cases of malignant gliomas (MGs) with epithermal neutron irradiations. Recently, we showed the early radiographical improvement of malignant glioma patients by our modified BNCT, with simultaneous use of BPA (borono-phenylalanine) and BSH (sodium borocaptate). In this time, we focused on the survival benefit from BNCT for the newly diagnosed glioblastoma patients. Methods: BNCT group including 21 newly histological confirmed glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002-2006 period. Ten patients were treated with BNCT only, and in the other 11 patients, 20-30 Gy fractionated external beam X-ray irradiation therapy (XRT) was performed after BNCT. No chemotherapy was administered until tumor progression was observed. Results: Treatments were well tolerated. Any kind of acute systemic or local severe toxicity were not demonstrated. Mean over all survival of the patients treated by BNCT was 20.7 and the median was 15.6 months with 2-years survival of 25%. Stratification by RPA criteria showed 6, 6, 8 and 1 patients, respectively, in classes III-VI. Three patients out of six in class III and one out of eight in class V are alive at the end point of this study. All the patients in classes IV and VI died. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6 months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. Conclusion: The RTOG RPA prognostic criteria were helpful in establishing which class of glioma patients could potentially benefit from BNCT. BNCT showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.

Original languageEnglish
JournalApplied Radiation and Isotopes
Volume67
Issue number7-8 SUPPL.
DOIs
Publication statusPublished - Jul 2009

Fingerprint

therapy
boron
neutrons
phenylalanine
prognosis
neutron irradiation
chemotherapy
stratification
progressions
toxicity
tumors
sodium
irradiation

Keywords

  • Boron neutron capture therapy
  • BPA
  • BSH
  • External beam X-ray irradiation
  • Glioblastoma

ASJC Scopus subject areas

  • Radiation

Cite this

Kawabata, S., Miyatake, S. I., Nonoguchi, N., Hiramatsu, R., Iida, K., Miyata, S., ... Ono, K. (2009). Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. Applied Radiation and Isotopes, 67(7-8 SUPPL.). https://doi.org/10.1016/j.apradiso.2009.03.015

Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. / Kawabata, Shinji; Miyatake, Shin Ichi; Nonoguchi, Naosuke; Hiramatsu, Ry; Iida, Kyoko; Miyata, Shiro; Yokoyama, Kunio; Doi, Atsushi; Kuroda, Yuzo; Kuroiwa, Toshihiko; Michiue, Hiroyuki; Kumada, Hiroaki; Kirihata, Mitsunori; Imahori, Yoshio; Maruhashi, Akira; Sakurai, Yoshinori; Suzuki, Minoru; Masunaga, Shin Ichiro; Ono, Koji.

In: Applied Radiation and Isotopes, Vol. 67, No. 7-8 SUPPL., 07.2009.

Research output: Contribution to journalArticle

Kawabata, S, Miyatake, SI, Nonoguchi, N, Hiramatsu, R, Iida, K, Miyata, S, Yokoyama, K, Doi, A, Kuroda, Y, Kuroiwa, T, Michiue, H, Kumada, H, Kirihata, M, Imahori, Y, Maruhashi, A, Sakurai, Y, Suzuki, M, Masunaga, SI & Ono, K 2009, 'Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients', Applied Radiation and Isotopes, vol. 67, no. 7-8 SUPPL.. https://doi.org/10.1016/j.apradiso.2009.03.015
Kawabata, Shinji ; Miyatake, Shin Ichi ; Nonoguchi, Naosuke ; Hiramatsu, Ry ; Iida, Kyoko ; Miyata, Shiro ; Yokoyama, Kunio ; Doi, Atsushi ; Kuroda, Yuzo ; Kuroiwa, Toshihiko ; Michiue, Hiroyuki ; Kumada, Hiroaki ; Kirihata, Mitsunori ; Imahori, Yoshio ; Maruhashi, Akira ; Sakurai, Yoshinori ; Suzuki, Minoru ; Masunaga, Shin Ichiro ; Ono, Koji. / Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients. In: Applied Radiation and Isotopes. 2009 ; Vol. 67, No. 7-8 SUPPL.
@article{fc20a1de2dc940a8806842228d3623f1,
title = "Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients",
abstract = "Objective: Since 2002-2007, we applied boron neutron capture therapy (BNCT) to >50 cases of malignant gliomas (MGs) with epithermal neutron irradiations. Recently, we showed the early radiographical improvement of malignant glioma patients by our modified BNCT, with simultaneous use of BPA (borono-phenylalanine) and BSH (sodium borocaptate). In this time, we focused on the survival benefit from BNCT for the newly diagnosed glioblastoma patients. Methods: BNCT group including 21 newly histological confirmed glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002-2006 period. Ten patients were treated with BNCT only, and in the other 11 patients, 20-30 Gy fractionated external beam X-ray irradiation therapy (XRT) was performed after BNCT. No chemotherapy was administered until tumor progression was observed. Results: Treatments were well tolerated. Any kind of acute systemic or local severe toxicity were not demonstrated. Mean over all survival of the patients treated by BNCT was 20.7 and the median was 15.6 months with 2-years survival of 25{\%}. Stratification by RPA criteria showed 6, 6, 8 and 1 patients, respectively, in classes III-VI. Three patients out of six in class III and one out of eight in class V are alive at the end point of this study. All the patients in classes IV and VI died. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6 months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. Conclusion: The RTOG RPA prognostic criteria were helpful in establishing which class of glioma patients could potentially benefit from BNCT. BNCT showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.",
keywords = "Boron neutron capture therapy, BPA, BSH, External beam X-ray irradiation, Glioblastoma",
author = "Shinji Kawabata and Miyatake, {Shin Ichi} and Naosuke Nonoguchi and Ry Hiramatsu and Kyoko Iida and Shiro Miyata and Kunio Yokoyama and Atsushi Doi and Yuzo Kuroda and Toshihiko Kuroiwa and Hiroyuki Michiue and Hiroaki Kumada and Mitsunori Kirihata and Yoshio Imahori and Akira Maruhashi and Yoshinori Sakurai and Minoru Suzuki and Masunaga, {Shin Ichiro} and Koji Ono",
year = "2009",
month = "7",
doi = "10.1016/j.apradiso.2009.03.015",
language = "English",
volume = "67",
journal = "Applied Radiation and Isotopes",
issn = "0969-8043",
publisher = "Elsevier Limited",
number = "7-8 SUPPL.",

}

TY - JOUR

T1 - Survival benefit from boron neutron capture therapy for the newly diagnosed glioblastoma patients

AU - Kawabata, Shinji

AU - Miyatake, Shin Ichi

AU - Nonoguchi, Naosuke

AU - Hiramatsu, Ry

AU - Iida, Kyoko

AU - Miyata, Shiro

AU - Yokoyama, Kunio

AU - Doi, Atsushi

AU - Kuroda, Yuzo

AU - Kuroiwa, Toshihiko

AU - Michiue, Hiroyuki

AU - Kumada, Hiroaki

AU - Kirihata, Mitsunori

AU - Imahori, Yoshio

AU - Maruhashi, Akira

AU - Sakurai, Yoshinori

AU - Suzuki, Minoru

AU - Masunaga, Shin Ichiro

AU - Ono, Koji

PY - 2009/7

Y1 - 2009/7

N2 - Objective: Since 2002-2007, we applied boron neutron capture therapy (BNCT) to >50 cases of malignant gliomas (MGs) with epithermal neutron irradiations. Recently, we showed the early radiographical improvement of malignant glioma patients by our modified BNCT, with simultaneous use of BPA (borono-phenylalanine) and BSH (sodium borocaptate). In this time, we focused on the survival benefit from BNCT for the newly diagnosed glioblastoma patients. Methods: BNCT group including 21 newly histological confirmed glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002-2006 period. Ten patients were treated with BNCT only, and in the other 11 patients, 20-30 Gy fractionated external beam X-ray irradiation therapy (XRT) was performed after BNCT. No chemotherapy was administered until tumor progression was observed. Results: Treatments were well tolerated. Any kind of acute systemic or local severe toxicity were not demonstrated. Mean over all survival of the patients treated by BNCT was 20.7 and the median was 15.6 months with 2-years survival of 25%. Stratification by RPA criteria showed 6, 6, 8 and 1 patients, respectively, in classes III-VI. Three patients out of six in class III and one out of eight in class V are alive at the end point of this study. All the patients in classes IV and VI died. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6 months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. Conclusion: The RTOG RPA prognostic criteria were helpful in establishing which class of glioma patients could potentially benefit from BNCT. BNCT showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.

AB - Objective: Since 2002-2007, we applied boron neutron capture therapy (BNCT) to >50 cases of malignant gliomas (MGs) with epithermal neutron irradiations. Recently, we showed the early radiographical improvement of malignant glioma patients by our modified BNCT, with simultaneous use of BPA (borono-phenylalanine) and BSH (sodium borocaptate). In this time, we focused on the survival benefit from BNCT for the newly diagnosed glioblastoma patients. Methods: BNCT group including 21 newly histological confirmed glioblastoma patients treated with surgical removal followed by BNCT in Osaka Medical College during 2002-2006 period. Ten patients were treated with BNCT only, and in the other 11 patients, 20-30 Gy fractionated external beam X-ray irradiation therapy (XRT) was performed after BNCT. No chemotherapy was administered until tumor progression was observed. Results: Treatments were well tolerated. Any kind of acute systemic or local severe toxicity were not demonstrated. Mean over all survival of the patients treated by BNCT was 20.7 and the median was 15.6 months with 2-years survival of 25%. Stratification by RPA criteria showed 6, 6, 8 and 1 patients, respectively, in classes III-VI. Three patients out of six in class III and one out of eight in class V are alive at the end point of this study. All the patients in classes IV and VI died. Median survival time for the BNCT group compared to the RTOG database was as follows: 20.6 months vs. 17.9 months for class III; 16.9 months vs. 11.1 months for class IV; 13.2 months vs. 8.9 months for class V. Conclusion: The RTOG RPA prognostic criteria were helpful in establishing which class of glioma patients could potentially benefit from BNCT. BNCT showed a survival benefit in all of the RPA classes of the RTOG database not only for the good prognosis group.

KW - Boron neutron capture therapy

KW - BPA

KW - BSH

KW - External beam X-ray irradiation

KW - Glioblastoma

UR - http://www.scopus.com/inward/record.url?scp=67649390794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649390794&partnerID=8YFLogxK

U2 - 10.1016/j.apradiso.2009.03.015

DO - 10.1016/j.apradiso.2009.03.015

M3 - Article

C2 - 19398348

AN - SCOPUS:67649390794

VL - 67

JO - Applied Radiation and Isotopes

JF - Applied Radiation and Isotopes

SN - 0969-8043

IS - 7-8 SUPPL.

ER -